Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study

Weniger, Maximilian; Moir, John; Damm, Marko; Maggino, Laura; Kordes, Maximilian; Rosendahl, Jonas; Ceyhan, Gueralp O.; Schorn, Stephan; RESPECT\\-Study Grp

doi:10.1016/j.suronc.2020.08.031

Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study

Date

2020

Authors

dc.identifier.doi

10.1016/j.suronc.2020.08.031

dc.identifier.other

WOS:000600199100021

Publisher

ELSEVIER SCI LTD

DOI

10.1016/j.suronc.2020.08.031

Keywords

Neoadjuvant chemotherapy , Survival , Advanced age

URI

https://openaccess.acibadem.edu.tr/handle/11443/7495

Collections

WOS

Full item page

Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By